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Abstract 
Purpose: To evaluate whether Siamese crocodile plasma exhibits antibacterial properties and if it 
synergizes with ceftazidime against ceftazidime-resistant Enterobacter cloacae (CREnC).  
Methods: Protein fractions were from crocodile plasma and tested them on CREnC strains. Multiplex 
polymerase chain reaction (PCR) screening test was performed for extended-spectrum β-lactamase 
(ESBL) phenotype and AmpC gene. The effects of the antibacterial agents were analyzed using a 
bacterial suspension standard curve, minimum inhibitory concentration (MIC), Checkerboard assays, 
viability curves, membrane permeability assays, enzyme assays, and transmission electron microscopy.  
Results: CREnC strains expressed ESBL-AmpC gene combinations. The MICs of resuspended protein 
1 (P1), protein 5 (P5), ceftazidime, cefotaxime, and benzylpenicillin against all tested CREnC and E. coli 
strains were in the range of > 1024 µg/mL, indicating resistance. However, P1 and P5 exhibited a 
synergistic effect against test CREnC and E. coli strains when used in combination with ceftazidime and 
cefotaxime, with fraction inhibitory concentration indices of < 0.062 and 0.28, respectively. A kill curve 
demonstrated that the combination treatments had synergistic activity and inhibited β-lactamase.  
Conclusion: The synergistic activity of P1 and P5 in combination with ceftazidime is achieved in 
multiple ways, including increased cytoplasmic and outer membrane permeability, β-lactamase 
inhibition, and peptidoglycan damage. Therefore, the combination therapy of Siamese crocodile plasma 
and ceftazidime may be a novel therapeutic approach for treating recalcitrant E. cloacae infection. 
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A widespread increase in antimicrobial 
resistance of the Enterobacteriaceae family has 
created a significant challenge for treatment. In 
particular, Enterobacter cloacae is a causative 
pathogen for a variety of infections in several 
organ systems, including circulatory, 
gastrointestinal, respiratory, urinary, central 
nervous, musculoskeletal, and integumentary 
system [1]. From 2011 to 2013, the multidrug-
resistant (MDR) rates (%) of E. cloacae identified 
-----------------------------------------------------------------------------------------------------------------------------------------------------
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from ICU and non-ICU infections in North 
America and Europe were 12.2 (ICU) and 10.0 
(non-ICU), and 18.2 (ICU) and 15.5 (non-ICU), 
respectively [2]. Resistance to extended-
spectrum cephalosporins occurs in 
approximately 31 % of Enterobacter spp 
identified in ICUs in the United States [3], and 
effective antibiotics to treat bacterial infections 
driven by producers of extended-spectrum β-
lactamases (ESBLs), β-lactamases of the AmpC 
type, or co-expressing ESBLs are sorely lacking 
[4]. Accordingly, development of novel 
antibacterials is in significant demand and 
represent a critical unmet need. 
 
Animals provide a unique source for novel 
antibacterial agents. For example, crocodiles 
suffer terrible fighting injuries without 
experiencing infections, even in pathogen-ridden 
water, indicating that crocodiles likely have an 
extremely potent immune system. Merchant and 
colleagues reported that the antibacterial 
spectrum of American alligator (Alligator 
mississippiensis) serum for both Gram-negative 
and positive species was more comprehensive 
than human serum [5]. In addition to the 
American alligator, the plasma of the Siamese 
crocodile (Crocodylus siamensis) has a broad 
antibacterial spectrum for Escherichia coli, 
Klebsiella pneumoniae, Salmonella typhi, 
Staphylococcus epidermidis, Staphylococcus 
aureus, Pseudomonas aeruginosa, and Vibrio 
cholera [6]. However, no studies have 
investigated the effects of the antibacterial action 
of Siamese crocodile (C. siamensis) plasma, or 
its synergistic action with ceftazidime against 
ceftazidime-resistant E. cloacae (CREnC).  
 
Hence, we used transmission electron 
microscopy (TEM), membrane permeability 
assays (outer membrane and cytoplasmic 
membrane), and β-lactamase inhibition assays to 
evaluate how Siamese crocodile plasma 
fractions, alone and in combination with 





Bacterial strains and antibiotics 
 
Clinical isolates of CREnC DMST 21394, DMST 
21549, DMST 19719, and E. coli DMST 20662, 
29237, 29239 were obtained from the Ministry of 
Public Health in Thailand. We obtained E. coli 
ATCC 25922 from the American Type Culture 
Collection (ATCC), USA, and used it as a 
reference strain. An 18 h culture was prepared at 
37 °C using Cation-adjusted Mueller-Hinton broth 
(CAMHB), purchased from Oxoid (Basingstoke, 
United Kingdom). Bovine serum albumin (BSA), 
ceftazidime (CTZ), cefotaxime (CFT), 
benzylpenicillin (BZP), nisin, and polymixin B 
(PMX) were purchased from Sigma-Aldrich 
(Dorset, England). 
 
Separation of protein from crocodile plasma 
 
All animal experimental protocols were approved 
under the U.K. Animals (Scientific Procedures) 
Act, 1986 and the Animal Care and Use 
Committee of Suranaree University of 
Technology (approved serial number: 30/2553). 
Blood of 40 healthy Siamese crocodiles aged 
between 1 - 3 years (Sriracha Moda Farm, 
ChonBuri, Thailand) was drawn from a dorsal 
vein and subsequently kept in an EDTA tube at 4 
°C. Then, 40 mL of blood was centrifuged at 
4000 x g for 10 min. The resulting crude plasma 
was fractionated using ion exchange 
chromatography. Crude plasma was diluted in 
Tris-HCl buffer (Tris-HCl, 25 mM, pH 8.1) and 
placed in a Q-Sepharose fast flow column (size = 
25 mL), then eluted with a linear NaCl gradient in 
Tris-HCl buffer (varying concentrations of NaCl at 
pH 8.1 included 0.1, 0.2, 0.3, 0.4 and 0.5 M for 
fractions 1, 2, 3, 4, and 5, respectively). To 
obtain only protein fractions, salt was eliminated 
and dialyzed overnight against diethyl-aminoethyl 
buffer (DEAE) using a dialysis membrane 
(Spectra/Por 1) (Spectrum, Houston, TX, USA, 
cut off 250 kDa) [7].  
 
The protein fractions were monitored 
spectrophotometrically and pooled to give 5 
fractions. We used ion exchange 
chromatography to further separate the pooled 
fractions. DEAE-Toyopearl 650 M (65 μm particle 
size) anion exchange resin was equilibrated 
using Tris-Chul buffer and elution from the 
column was performed in Tris-HCl buffer using a 
linear gradient of NaCl and infiltration of the 
column with trifluoroacetic acid (0.1 %). The 
molecular weights (MW) of proteins contained in 
the separated protein 1 (P1) to separated protein 
5 (P5) fractions were evaluated using SDS-
PAGE. Separated fractions were lyophilized and 
stored at - 70 °C. Protein concentrations of 
resuspended P1 and P5 were measured using a 
Coomassie assay [8], and standard curves were 
generated using BSA.  
 
Screening test for ESBL phenotype and 
AmpC gene detection 
 
The presence of ESBL, AmpC, and Metallo-β-
lactamase (MBL) in test E. cloacae strains was 
phenotypically determined as reported previously 
[9]. Briefly, 5 x 105 CFU/mL of the test bacteria 
were challenged with a serial two-fold dilution of 
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ceftazidime and cefotaxime with and without their 
respective inhibitors (4 µg/mL of clavulanic acid 
[ESBL inhibitor], 200 µg/mL of cloxacillin [AmpC 
inhibitor], and 0.5 mM of EDTA [MBL inhibitor]). 
The results were interpreted within 6 h of 
incubation at 37 °C by calculating the ratio of the 
MIC value of the well without β-lactamase 
inhibitors versus the MIC of the well with β-
lactamase inhibitors. An eightfold or higher MIC 
ratio denoted a positive result for the presence of 
β-lactamase. In addition, we performed multiplex 
PCR for screening and confirmation of genes for 
AmpC (DHA and EBC) and ESBL (CTX-M-3, 
CTX-M-14, SHV, SHV-5, and TEM) [10].  
 
Bacterial suspension standard curve 
 
We performed bacterial suspension standard 
curves as previously described, with a few 
modifications [11]. The modifications were 
CAMHB and Mueller Hinton agar was used as a 
culture medium instead of Iso-sensitest broth and 
Iso-sensitest agar, respectively [12]. 
 
Susceptibility test  
 
We determined the minimum inhibitory 
concentrations (MICs) for resuspended crocodile 
plasma fractions and antibiotics with a broth 
microdilution assay in a 96-well microtiter plate 
as previously described [12]. The susceptibility 
panel was prepared by dispensing 100 μL of 
2048 µg/mL resuspended P1 or P5 (with sterile 
water) into the first column wells, and 80 μL of 
CAMHB (pH 5.9) with 20 μL of 1 x 106 CFU/mL 
into the test wells to get a 1024 µg/mL 
suspension. Then, serial twofold dilutions of P1 
or P5 suspension were carried out by aliquoting 
100 μL of suspension in the first column wells 
into the second column; subsequent columns 
contained 20 μL of 5 x 106 CFU/mL diluted 
bacteria plus 80 μL of CAMHB. After 20 h at 37 
°C, the lowest concentration that did not induce 




The interaction between resuspended P1 and 
P5, and ceftazidime, cefotaxime, or 
benzylpenicillin against CREnC was determined 
using checkerboard assays, as described in 
Eumkeb et al. [13]. We determined the 
interactions between agents by calculating the 
fractional inhibitory concentration index (FICI) for 
each combination. We then determined each 
individual treatment fractional inhibitory 
concentration (FIC) by determining which 
concentration (when used in combination) 
completely inhibited bacterial growth. 
 
FICI was calculated using Equation 3 below: 
 
FICP1 = MICP1C/MICP1A …………… (1) 
 
FICC = MICCC/MICCA ………………. (2) 
 
FICI = FICP1 + FICC …………………. (3) 
 
Where FICP1 is the FIC of P1, MICP1C 
represents the P1 MIC in combinatorial 
treatments, MICP1A is the P1 MIC, FICC is the 
ceftazidime FIC, MICCC is the ceftazidime MIC 
in the combination, and MICCA is the MIC of 
ceftazidime alone. A FICI value of a combination 
 0.5 was considered synergistic; FICI > 0.5 - < 
1.0 was considered partially synergistic; FICI 
equal to 1.0 was considered additive; FICI > 1.0 - 
≤ 4.0 was considered indifferent; and FICI > 4.0 




Kill curves were performed according to a 
previous report with minor modifications [13]. 
Inocula of 5x105 CFU/mL of CREnC 21394 were 
exposed to individual antibacterial agents, used 
at half-MIC concentrations (512 µg/mL). In 
combination experiments, concentrations of the 
individual compounds were used at the MIC 
required for synergism (32 µg/mL). Cultures 
containing either 0.9 % Sodium chloride (NaCl), 
this was the vehicle treatment condition, or BSA 
(512 µg/mL) were used as controls. 
 
Transmission electron microscopy (TEM) 
 
We used a previously reported method to 
evaluate bacterial structure and morphology by 
TEM following treatment with test compounds 
[15]. We chose to use half-MIC for each 
individual agent (P1 at 512 µg/mL, P5 at 512 
µg/mL, or ceftazidime at 512 µg/mL), and used 
concentrations below the FIC for each 
combination (P1 at 16 µg/mL plus ceftazidime at 
16 µg/mL and P5 at 16 µg/mL plus ceftazidime at 
16 µg/mL). This ensured that most of the 
bacteria were damaged, but not killed. Briefly, 
adjusted 4 h log phase cultures (5 x 105 
CFU/mL) were exposed to antibacterial 
compounds and resuspended fractions.  
 
The cells were pelleted, fixed, dehydrated, 
infiltrated, and embedded. Sectioned samples 
were counterstained and examined with a Tecnai 
G2 electron microscope. Using micrographs, we 
evaluated the effects of the agents on cell size by 
quantifying cell area (nm2) (cell width x cell 
length). Experiments were repeated three times, 
and data is reported as the mean ± SEM. 
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Outer membrane (OM) permeability assay 
 
OM permeability of CREnC 21394 in response to 
individual and combination treatments of P1 (512 
μg/mL), P5 (512 μg/mL), ceftazidime (512 
μg/mL), and ceftazidime (16 μg/mL) plus 16 
μg/mL of either P1 or P5, was determined using 
a nitrocefin assay as described in [16]. Briefly, 
inocula of log phase cultures were treated with 
resuspended P1, P5, and ceftazidime at the 
same concentrations used for TEM. Nitrocefin 
(20 µg/mL) was used as the β-lactamase 
substrate. We measured the assay in a plate 
reader using a wavelength of 500 nm over 30 
min at 37 °C. Wells with 7 µg/mL polymixin B 
(positive control) and without antibacterial agents 
(negative control) were also included. 
 
Cytoplasmic membrane (CM) permeability 
assay 
 
We evaluated CM permeability with slight 
modifications of previous methods [16]. Briefly, 
we mixed suspended cells (50 μL, OD = 0.3) in 
wells containing 50 μL of ortho-Nitrophenyl-β-
galactoside (ONPG), and the half-MICs of 
resuspended P1 (512 μg/mL), P5 (512 μg/mL), 
and ceftazidime (512 μg/mL) alone, or the half-
MICs of each combination (16 µg/mL P1 plus 16 
µg/mL ceftazidime and 16 µg/mL P5 plus 16 
µg/mL ceftazidime) that were established as 
synergistic FICIs (final concentration of ONPG = 
100 μg/mL). Plates were equilibrated to 
temperature, and ONPG consumption and 
intracytoplasmic cleavage were measured in a 
plate reader at 37 °C by monitoring absorption at 
420 nm for 120 min. Nisin-containing wells (0.5 
μg/mL, positive control) and untreated wells 
(negative control) were also included. 
 
β-lactamase inhibition assay 
 
We evaluated the ability of resuspended P1 and 
P5 to inhibit the  lactamase type IV (purified 
enzyme from E. cloacae; Sigma; Poole, England) 
by modifying previous methods [15]. We used 
100 µg/mL benzylpenicillin, (a β-lactamase type 
IV substrate); this concentration was chosen as it 
is 50 – 60 % hydrolyzed within 5 min. 
Resuspended P1, P5, and ceftazidime were 
preincubated at 37 °C with β-lactamase type IV 
in a buffer containing sodium phosphate (50 mM, 
pH 7.0) for 5 min, followed by addition of 
benzylpenicillin. We analyzed 5 timepoints from 0 
– 20 min, in increments of 5 min, and a solution 
of methanol and acetic acid (100:1) was used to 
stop the reaction. The uninhibited benzylpenicillin 
was quantified using reverse-phase HPLC. Ten 
microliters of each sample were analyzed using a 
10 mM ammonium acetate (pH 4.5 acetic 
acid):acetonitrile (75:25) mobile phase, at a flow 
rate of 1 mL/min, a 200 nm UV detector, and an 
Ascentis C18 column at 35 °C. The area under 
the curve was used to quantify the results. BSA-
treated (512 µg/mL; negative control) and 0.9 % 





CM and OM permeability and enzyme assays 
were carried out in triplicate. Average cell area 
was measured with TEM analysis. The data as 
shown as mean ± standard error of the mean 
(SEM). Statistical differences were evaluated 
using one-way ANOVA, and p < 0.01 by Tukey’s 





Siamese crocodile plasma-derived proteins 
 
Molecular weights from SDS-PAGE analysis of 
resuspended P1 and P5 fractions are depicted in 
Figure 1. The results showed that both 
resuspended P1 and P5 displayed two protein 
bands at 67 and 75 kDa. 
 
 
Figure 1: Molecular weight of proteins contained in re-
suspended P1 and P5 
 
ESBL phenotype and AmpC gene detection 
 
To establish the resistance profile for the CREnC 
used in this study, we performed a β-lactamase 
phenotypic assay, and found that all test CREnC 
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strains expressed both AmpC β-lactamases and 
ESBLs. These included the resistant EBC AmpC 
gene and the TEM ESBL gene, indicating that 
these strains are cephalosporin-resistant. 
Together, these findings reflect those reported 
previously by Eumkeb, Chukrathok, and Kao et 
al. who detected these resistance genes (ESBL-
AmpC combinations) in CREnC strains and 
multiple drug resistant E. cloacae isolates [10, 
15].  
 
MIC and checkerboard assay data 
 
The MIC results of resuspended P1, P5, CTZ, 
CFT, and BZP against CREnC strains were 
1024, 1024, > 1024, > 1024, and > 1024 µg/mL, 
respectively (Table 1). Additionally, test E. coli 
strains were inhibited by the MICs of CTZ, CFT, 
BZP, P1, and P5 at 512, 512, > 1024, 512, and 
512 µg/mL, respectively. In contrast, P2, P3, and 
P4 had MICs > 2048 µg/mL against all CREnC 
strains (data not shown), indicating that the 
active compound(s) is likely in P1 and P5. 
 
According to the Clinical Laboratory Standards 
Institute, all tested CREnC strains were highly 
resistant to ceftazidime, cefotaxime, and 
benzylpenicillin, whereas the reference strain 
was susceptible to these antibiotics [17]. These 
findings suggest that the resistance genes, the 
ESBL-AmpC combination expressed by CREnC 
strains leads to cephalosporin resistance. 
Checkerboard data for crocodile plasma fractions 
(P1 and P5) with both ceftazidime and 
cefotaxime against CREnC and E. coli strains 
had synergistic activity at FICIs < 0.062 and 
0.28, respectively. Likewise, benzylpenicillin plus 
either P1 or P5 displayed partially synergism at a 
FICI < 1.0 against all of the tested strains (Table 
2) [14]. 
 
Table 1: MICs of ceftazidime, cefotaxime, benzylpenicillin, P1, and P5 against ceftazidime-resistant E. cloacae 
(CREnC) and E. coli strains. Data represent the medians, generated from three triplicate experiments 
 
Strain MICs (g/mL) 
 CTZ CFT BZP P1 P5 
CREnC DMST 21394 >1024R >1024R >1024R 1024ND 1024ND 
CREnC DMST 21549 >1024R >1024R >1024R 1024ND 1024ND 
CREnC DMST 19719 >1024R >1024R >1024R 1024ND 1024ND 
E. coli DMST 20662 512R 512R >1024R 512ND 512ND 
E. coli DMS 29237 512R 512R >1024R 512 ND 512ND 
E. coli DMS 29239 512R 512R >1024R 512ND 512ND 
E. coli ATCC 25922* 0.25S 0.25S 1.0S 512ND 512ND 
*Positive control was E. coli (ATCC 25922). S = susceptible; R = resistance; ND = no data in Clinical Laboratory 
Standards Institute; CTZ = ceftazidime; CFT = cefotaxime; BZP = benzylpenicillin 
 
Table 2: FICs and FICIs of ceftazidime, cefotaxime, benzylpenicillin, P1, and P5 against ceftazidime-resistant E. 
cloacae (CREnC) and E. coli strains. Each experiment was performed in triplicate 
 
Strain FIC: FICI 



































































































* Positive control was E. coli (ATCC 25922). SI = synergistic; PS = partially synergistic; CTZ = ceftazidime; CFT = 
cefotaxime; BZP = benzylpenicillin. The FIC: FICI value of CTZ + P1 at 32+32: <0.062SI in each row below this 
column is the MIC of ceftazidime at 32 g/mL plus P1 at 32 g/mL in the combination. Accordingly, the FICI 
value of CTZ + P1 was < 0.062SI, which exhibited a synergistic interaction 
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Figure 2: Viability of CREnC 21394 after treatment with: () = Control (0.9 % NaCl); () = BSA; () = P1; () = 
P5; () = ceftazidime; () = P1 + ceftazidime; and () = P5 + ceftazidime. Compound and BSA concentrations 
were 512 µg/mL for individual treatments, and 32 µg/mL each for combination treatments. Data plotted are mean 
± SEM (n = 3) 
 
Kill curve data 
 
We next evaluated the effects of individual and 
combination treatment with ceftazidime, P1, and 
P5 on CREnC 21394 viability (Figure 2). 
Treatment with BSA, a negative control, like the 
untreated control, had no effects on viability. 
Similarly, individual treatment with ceftazidime, 
P1, or P5 slightly decreased viability. However, 
we found that combination treatment with 
ceftazidime and P1 or P5 remarkably decreased 
cell viability by 6 h, and reduced viability (to 5 x 
103 CFU/mL) was sustained until the end of the 
experiment (24 h). Our findings reflected those of 
the checkerboard assay, which demonstrated 
synergism of combination treatments, illustrated 
by decreased cell numbers (≥ 2log10 CFU/mL), 





To determine the effects of the antimicrobial 
agents on cellular structure, we performed TEM 
of clinical isolates of CREnC 21394 treated with 
resuspended P1, P5, and ceftazidime alone and 
in combination during the log phase of growth 
(Figure 3). 
 
The untreated control cells exhibited a standard 
appearance, with a normal peptidoglycan layer, 
and easily distinguished cytoplasmic membranes 
(Figure 3a). P1, P5, and ceftazidime individually 
treated cells are displayed in Figure 3b, 3c, and 
3d, and exhibit small disruptions in cell 
envelopes. The average cross-sectional area of 
individually treated cells was slightly less than 
that of control cells, but we found no statistically 
significant differences (p > 0.01) (Figure 4).   
 
Figure 3 e and f show the effects of re-
suspended P1 and P5 plus ceftazidime treatment 
on cell morphology. Most of the combination-
treated cells displayed obvious morphological 
changes, illustrated by irregular cell shapes. We 
observed changes in the outer membrane, 
peptidoglycan layer, and cytoplasmic membrane 
damage that resulted in ribosomal and leakage 
of intracellular material. Additionally, the 
combination treatments decreased cell area 
compared to that of cells treated individually or 
not at all (p < 0.01). Furthermore, the P5 and 
ceftazidime combination group exhibited the 




To evaluate the efficacy of P1, P5, ceftazidime, 
and combination treatments against bacterial 
membrane permeability, we measured OM 
permeability using nitrocefin cleavage as a 
readout. Our results revealed that resuspended 
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P1, P5, and ceftazidime alone caused a 
significant increase in OM permeability (p < 0.01) 
(Figure 5). Moreover, treatment with ceftazidime 
plus P1 or P5 resulted in significantly higher OM 
permeability than those of these agents treated 




Figure 3: TEM images of CREnC 21394 after 4 h of 
culture in CAMHB. a = Control, b = CREnC 21394 
treated with P1, c = CREnC 21394 treated with P5, d 
= CREnC 21394 treated with ceftazidime, e = CREnC 
21394 treated with ceftazidime plus resuspended P1, 
and f = CREnC 21394 treated with ceftazidime plus 
resuspended P5 (scale bar for a - c = 200 µm; d - f = 
500 µm). Compound concentration was 512 µg/mL for 
individual treatments, and 16 µg/mL each for 
combination treatment; 0.9 % NaCl was the vehicle 




To evaluate CM permeability in response to 
treatment with P1, P5, ceftazidime, or 
combinations of the three, we quantified ONPG 
cleavage by CREnC 21394 following treatment. 
We found that combination treatment with 
resuspended P1 or P5 plus ceftazidime resulted 
in significantly greater CM permeability, 
illustrated by increased OD levels compared to 
individual treatments and the control treatment (p 
< 0.01) (Figure 6). These results demonstrate 
that ceftazidime acts synergistically with P1 or P5 
to increase CM permeability, suggesting that 





Next, we evaluated the efficacy of different 
treatments on β-lactamase inhibition by 
quantifying the ability of β-lactamase to break 
down benzylpenicillin. We found that the 
combination of P1 or P5 plus ceftazidime 
treatment inhibited benzylpenicillin depletion, 
compared to untreated controls and individually 
treated cells (p < 0.01). In addition, individual P1, 
P5, and ceftazidime treatment resulted in 
significantly higher remaining benzylpenicillin 




We compared the MWs of resuspended P1 - P5 
fractions using SDS-PAGE (23 - 160 kDa), with 
those described in a previous report by Threenet 
et al., who found that the protein profiles of 
Siamese crocodile serum presented 6 bands at 
MWs 225, 121, 67, 62, 45, and 25 kDa, 
respectively [19]. Therefore, the range of P1 - P5 
MWs in our study was consistent with that 
previously reported. 
 
Crocodile-derived antibacterial has shown some 
success to date. For example, crocosin isolated 
from C. siamensis plasma inhibits the growth of 
susceptible strains of S. typhi and S. aureus [20]. 
In addition, another study demonstrated that 
Crocodylus siamensis hepcidin (Cshepc) has 
antibacterial properties and inhibits growth of 
Gram-negative and Gram-positive bacterial 
species [21].  
 
Using a checkerboard assay, we found that both 
resuspended P1 and P5 plus ceftazidime, 
cefotaxime, or benzylpenicillin exhibited very 
high, high, or partial synergistic activity 
respectively against CREnC strains.  
 
Our findings demonstrate that the resistance of 
these CREnC strains, which express ESBL-
AmpC combination resistance genes, was 
reversed by combining ceftazidime treatment 
with either resuspended P1 or P5, which 
significantly increased the efficacy of ceftazidime. 
Additionally, we found that resuspended P1 and 
P5 exhibited greater effects in combination with 
cetazidime and cefotaxime than benzylpenicillin. 
Our kill curve results confirmed that the 
bactericidal effects of P1 or P5 synergize with 
ceftazidime, demonstrated by a decrease in 
viability ≥ 3log10 CFU/mL [22]. Similarly, other 
compounds, including apigenin and naringenin 
also enhance ceftazidime activity against CREnC 
strains [15]. 
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Figure 4: Quantification of cell area following treatment with: Con = control; P1 (512) = P1 (512 µg/mL); P5 (512) 
= P5 (512 µg/mL); Cef (512) = ceftazidime (512 µg/mL); cef (16) + P1 (16) = ceftazidime + P1 (both 16 µg/mL); 
and cef (16) + P5 (16) = ceftazidime + P5 (both 16 µg/mL); 0.9 % NaCl was the vehicle treatment applied. Data 
are mean ± SEM (n = 3). Different letters indicate groups with statistical significance compared with other groups 




Figure 5: CREnC 21394 OM permeability measurements over time following exposure to: () = Control; () = 
P1; () = P5; () = ceftazidime; () = ceftazidime + P1; () = ceftazidime + P5; and () = polymixin B (7 
µg/mL). Compound concentration was 512 µg/mL for individual treatments and 16 µg/mL each for combination 
treatment; 0.9 % NaCl was used as vehicle control. The data are plotted are mean ± SEM (n = 3). Different letters 
indicate groups with statistical significance compared with other groups (Tukey’s HSD test, p < 0.01)  
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Figure 6: CREnC 21394 CM permeability measurements over time following exposure to: () = Control; () = 
P1; () = P5; () = ceftazidime; () = ceftazidime + P1; () = ceftazidime + P5; and () = Nisin (8 µg/mL). 
Compounds were used at 512 µg/mL for individual treatments, and at 16 µg/mL each for combination treatments; 
0.9 % NaCl was used as vehicle control. Data plotted are mean ± SEM (n = 3). Different letters indicate groups 




Figure 7: Inhibitory effect of resuspended P1 or P5 on β-lactamase activity. The graph illustrates remaining 
benzylpenicillin for each treatment group at different timepoints. () = control (0.9 % NaCl); () = BSA (negative 
control); () = P1; () = P5; () = ceftazidime; () = ceftazidime + P1; and () = ceftazidime + P5. Compound 
concentration was 512 µg/mL for individual treatments and 16 µg/mL for each combination treatments; 0.9 % 
NaCl was the vehicle treatment applied. Data plotted are mean ± SEM (n = 3). Different letters indicate groups 
with statistical significance compared with other groups (Tukey’s HSD test, p < 0.01) 
 
Our TEM results demonstrate that cells treated 
with a combination of either P1 or P5 plus 
ceftazidime revealed clear morphological 
damage and significantly decreased cell area. 
These results are consistent with earlier findings 
that Siamese crocodile (C. siamensis) crude 
plasma or plasma fractions caused roughening 
and blebbing of the cell membrane of S. aureus, 
S. typhi, E. coli, V. cholerae, P. aeruginosa, and 
S. epidermidis [6, 20].  
 
Combination treatment of ceftazidime with 
resuspended P1 or P5 significantly increased 
OM permeabilization of CREnC cells compared 
to control. This enhancement of OM permeability 
enhancement may be due to the presence of 
Rojtinnakorn et al 
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cationic polypeptides in the resuspended protein 
fractions that may interact via hydrophilic 
interfacing with the lipopolysaccharide core, or 
interact electrostatically, disrupting the polarity of 
the core and blocking interactions between 
saccharides [23]. Similarly, the novel 
antibacterial peptides Leucrocin I (molecular 
mass, approx 806.99 Da) and Leucrocin II 
(molecular mass, approx. 956.3 Da), isolated 
from white blood cells of C. siamensis, have 
been reported to combat S. epidermidis, S. typhi, 
and V. cholerae by increasing OM permeability 
[24].  
 
The CM permeability findings suggest that one 
mechanism of action of resuspended protein 
fractions and ceftazidime combination treatment 
may be through increasing non-specific CM 
permeability, which results in cell death following 
leakage of cellular contents. This is similar to a 
report that found that apigenin and ceftazidime 
treatment promotes CREnC CM permeability 
[15].   
 
β-lactamase plays a crucial role in inactivating β-
lactam antibiotics by cleaving their β-lactam ring, 
resulting in loss of bactericidal efficacy. 
Additionally, a previous study reported that 
clavulanic acid, a -lactamase inhibitor that has 
played an important role in fighting -lactam-
resistant bacteria, activity is lost through the 
same mechanism as β-lactam antibiotics [25]. 
Since P1 and P5 are structurally unlike clavulanic 
acid, P1 and P5 may not stimulate β-lactamase 
induction. Unlike resuspended P1 or P5, 
conventional β-lactamase inhibitors cannot 
reverse bacterial resistance [15]. 
 
The β-lactamase inhibition assay demonstrated 
that the benzylpenicillin level of the ceftazidime-
treated group remaining following the assay was 
higher than BSA-treated and control groups. 
Furthermore, the highest remaining of 
benzylpenicillin levels were observed following 
P5 and ceftazidime combination treatment. 
These findings provide evidence that β-
lactamase, an enzyme that hydrolyzes the -
lactam ring of the -lactam antibiotics results in 
loss of bactericidal activity, from E. cloacae 
(penicillinase from E. cloacae) may act more 
slowly on ceftazidime than benzylpenicillin, both 
drugs contain a -lactam ring, due to the fact that 




Data from this study demonstrate that 
resuspended P1 or P5 from crocodile plasma, in 
combination with ceftazidime or cefotaxime has a 
synergistic effect against CREnC strains. The 
synergistic activity of these combinations may be 
due to OM and CM disruption, resulting in 
increased cell permeability, inhibition of β-
lactamase activity, and potential damaging 
effects on the peptidoglycan structure. Therefore, 
it seems that P1 or P5 can be used in 
combination with ceftazidime to treat ceftazidime-
resistant E. cloacae infection, which is currently 
resistant to the majority of antibiotics. Additional 
studies will determine whether this therapeutic 
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